ERBB2 and breast carcinoma: In combination with Margetuximab (a HER2 Mab), they have also demonstrated favorable therapeutic effects in breast cancer patients previously received anti-HER2 therapy (n = 4/30; ORR, 13.3%; Fig. 5a and Supplementary Table S6) [174].